224 related articles for article (PubMed ID: 35652618)
21. Impact of pre-treatment variables on the completion of
Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
[TBL] [Abstract][Full Text] [Related]
22. Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.
van der Doelen MJ; Stockhaus A; Ma Y; Mehra N; Yachnin J; Gerritsen WR; Nilsson S; van Oort IM; Ullén A
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3325-3334. PubMed ID: 33686456
[TBL] [Abstract][Full Text] [Related]
23. Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis.
Turco F; Tucci M; Angusti T; Parente A; Di Stefano RF; Urban S; Pisano C; Samuelly A; Audisio A; Audisio M; Parlagreco E; Ungaro A; Scagliotti GV; Di Maio M; Buttigliero C
Tumori; 2023 Apr; 109(2):233-243. PubMed ID: 35361017
[TBL] [Abstract][Full Text] [Related]
24. A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
Badrising SK; Louhanepessy RD; van der Noort V; Coenen JLLM; Hamberg P; Beeker A; Wagenaar N; Lam MGEH; Celik F; Loosveld OJL; Oostdijk A; Zuetenhorst H; Haanen JB; Vegt E; Zwart W; Bergman AM;
Int J Cancer; 2020 Aug; 147(4):1143-1151. PubMed ID: 31875956
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific antigen flare induced by
Castello A; Macapinlac HA; Lopci E; Santos EB
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
[TBL] [Abstract][Full Text] [Related]
26. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
George DJ; Agarwal N; Sartor O; Sternberg CN; Tombal B; Saad F; Miller K; Constantinovici N; Guo H; Reeves J; Jiao X; Sandström P; Verholen F; Higano CS; Shore N
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):306-313. PubMed ID: 35190653
[TBL] [Abstract][Full Text] [Related]
27. The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Bauckneht M; Rebuzzi SE; Signori A; Frantellizzi V; Murianni V; Lodi Rizzini E; Mascia M; Lavelli V; Donegani MI; Ponzano M; Gaudiano A; Stazza ML; Licari M; Cavallini L; Laghi V; Cindolo L; Maggi M; Sciarra A; Mammucci P; Sambuceti G; Costa RP; Spanu A; Rubini G; Monari F; De Vincentis G; Fornarini G
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1063-1074. PubMed ID: 34486070
[TBL] [Abstract][Full Text] [Related]
28. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
[TBL] [Abstract][Full Text] [Related]
29. Radium-223 in the Third-Line Setting in Metastatic Castration-Resistant Prostate Cancer: Impact of Concomitant Use of Enzalutamide on Overall Survival (OS) and Predictors of Improved OS.
Ahmed ME; Joshi VB; Badawy M; Pagliaro LC; Karnes RJ; Lowe V; Thorpe MP; Kwon ED; Kendi AT
Clin Genitourin Cancer; 2021 Jun; 19(3):223-229. PubMed ID: 33632570
[TBL] [Abstract][Full Text] [Related]
30. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT
Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839
[TBL] [Abstract][Full Text] [Related]
31. Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan.
Chiang PC; Chiang PH; Chen IA; Chen YT; Wang HJ; Cheng YT; Kang CH; Chen CH; Liu YY; Su YL; Chen YH; Luo HL
Medicine (Baltimore); 2023 Feb; 102(5):e32671. PubMed ID: 36749250
[TBL] [Abstract][Full Text] [Related]
32.
Boni G; Mazzarri S; Cianci C; Galli L; Farnesi A; Borsatti E; Bortolus R; Fratino L; Gobitti C; Lamaj E; Ghedini P; Rizzini EL; Massari F; Dionisi V; Fanti S; Volterrani D; Monari F
Tumori; 2018; 104(2):128-136. PubMed ID: 29714668
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
34. Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
Satapathy S; Das CK; Aggarwal P; Sood A; Parihar AS; Singh SK; Mittal BR
Prostate; 2023 Feb; 83(2):169-178. PubMed ID: 36259290
[TBL] [Abstract][Full Text] [Related]
35. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
[TBL] [Abstract][Full Text] [Related]
36. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223.
Nome R; Hernes E; Bogsrud TV; Bjøro T; Fosså SD
Scand J Urol; 2015 Jun; 49(3):211-7. PubMed ID: 25515952
[TBL] [Abstract][Full Text] [Related]
37. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
[TBL] [Abstract][Full Text] [Related]
38. Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis.
Dong B; Yang B; Chen W; Du X; Fan L; Yao X; Xue W
Med Oncol; 2022 May; 39(5):96. PubMed ID: 35599270
[TBL] [Abstract][Full Text] [Related]
39. Treatment outcomes of radium-223 in patients with metastatic castration-resistant prostate cancer: An experience before National Health Insurance reimbursement in Taiwan.
Yu PH; Wei TT; Chang YH; Chung HJ; Huang EY; Lin TP; Huang WJ
J Chin Med Assoc; 2023 Aug; 86(8):756-761. PubMed ID: 37314313
[TBL] [Abstract][Full Text] [Related]
40. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
